SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: Bluegreen who wrote (14653)9/16/2000 9:35:08 PM
From: Cacaito  Respond to of 17367
 
"antibacterial effects" in animals is proven. In humans the benefit is to be proven. Yes, I do stil has hope it will turn into a good antibiotic. I even has hope that the abdominal indication is the next one and better chances of success cause a trial is easier to execute due to the very common nature of the disorder, and the in many ways less acute, and sometimes subacute characteristics of abdominal infections, actually the pIIpIII trauma combined data should have interesting findings regarding 2ry infections due to perforated bowels, pII trauma showed a trend and the pI/II abdominal infection showed a trend. But the pay off is much less for a success in this area. Again, how cheap is to produce bpi.

No one commented on the Glaxo/Dna mab court fight.

Gw is not helping with the sutro/private/pj sequence, He is usually good in the financial aspects (actually quite good).

It is very important, cause if Pj job is just getting the last private investors (5.5 million shares at $5.5 each)out of the hook (getting the long termers to pick the tab), then the stock is on the way back down to the usual $3 to $5
(ok, no more $ub1, almost got there!).

Last group of privates 5.5 million shares, as good as I can remember, did not mentioned any investment house, I assumed that a lesser one or even Sutro was involved but it was not disclosed that way at the time, neither anyone else, then logically Pj is doing the job.

Different cheese, same rat.